Evaluation of efficacy and safety of Terbinafine, Fluconazole and Itraconazole in skin fungal infections

Evaluation of efficacy and safety of Terbinafine, Fluconazole and Itraconazole in superficial mycoses - A Prospective, randomized, controlled, cost- effective analysis study - TER/FLU/ITRA

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/04/013303

Enrollment

Registered

2018-04-16

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Terbinafine: 250 mg oral once daily for 30 days Control Intervention1: Tab. Fluconazole: 150 mg oral, once daily for 30 days Control Intervention2: Tab. Itraconazole: 100 mg, oral, once

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients aged between 18 - 60 years of either sex. 2. Patients freshly diagnosed 3. Patients willing to give written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients hypersensitive to study drugs. 2. Pregnant and lactating women. 3. Patients having pre-existing renal, liver and cardiac illness. 4. Patients already on treatment with topical antifungal agents.

Design outcomes

Primary

Measure	Time frame
To assess the clinical efficacy and mycological clearance, and patient’s compliance.Timepoint: 0 day,15 day, 30 day	—

Secondary

Measure	Time frame
Adverse effects and cost-effectivenessTimepoint: 0 day,15 day, 30 day	—

Countries

India

Contacts

Public ContactDr M Padmaja

Nizams Institute of Medical Sciences,

thippana.padmaja@gmail.com9100953423

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026